ABBV vs JNJ
ABBV and JNJ side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABBVAbbVie Inc. | JNJJohnson & Johnson |
|---|---|---|
| Market cap | $520.97B | $657.80B |
| P/E (TTM) | 83.3 | 41.5 |
| P/B | — | 8.07 |
| P/S | 8.5x | 7.0x |
| Dividend yield | 2.24% | 1.88% |
| Revenue | $61.16B(TTM) | $99.33B(TTM) |
| Revenue growth (YoY) | 8.6% | 6.0% |
| Net income | $6.31B(TTM) | $16.09B(TTM) |
| Earnings growth (YoY) | -1.2% | 90.6% |
| EPS, diluted | $3.54(TTM) | $6.58(TTM) |
| EBIT margin | 24.6% | 22.9% |
| ROE | — | 32.9% |
| ROIC | 18.6% | 16.3% |
| Piotroski F | — | 6/9 |
| 1y total return | +32.0% | +47.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABBV vs JNJ
| Metric | ABBV | JNJ |
|---|---|---|
| End value | $73.0K | $30.2K |
| Total return | +629.9% | +202.5% |
| CAGR | +21.2% | +11.3% |
| Volatility | 25.8% | 18.8% |
| Sharpe | 0.72 | 0.44 |
| Sortino | 1.00 | 0.63 |
| Max drawdown | -45.1% | -27.4% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)